Sera Prognostics, Inc.
Moat Score — Sera Prognostics, Inc.
Total Moat Score
8 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Sera's proprietary biobank of longitudinal pregnancy samples and outcomes data, combined with its proteomics/bioinformatics platform, underpins the PreTRM test's validated claim that the company states no competitor currently matches, giving it real but still narrow and single-product-dependent intangible IP value. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a small-scale diagnostics company still building commercial volume, Sera has no demonstrated low-cost production or processing advantage versus larger reference laboratories; its unit economics are tied to a fixed payer reimbursement rate rather than a cost-leadership position. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | PreTRM's price is effectively anchored to a CMS reimbursement rate near $750 per test, leaving Sera with little independent pricing power; its path to better unit economics runs through broader payer coverage and volume, not price increases. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | A blood-based diagnostic test exhibits no network effect — one patient's or payer's use of PreTRM does not make the test more valuable or accurate for another patient. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Once a payer or health system adopts PreTRM into an obstetric care pathway there is some institutional inertia, but with no FDA-cleared alternative test to switch to or from in this specific indication, there isn't a strong switching-cost dynamic yet — the real battle is initial adoption, not retention against a rival. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Sera's proprietary biobank represents years of accumulated, hard-to-replicate sample and outcomes data that a new entrant would need significant time and capital to match, but the broader diagnostics-lab category is not inherently limited to only a few efficiently-scaled players, so this advantage is real but moderate. |